Quit Smoking Study for People Who Use E-Cigarettes

Nicotine Addiction Clinical Trial

Official title:

A Randomized Controlled Trial of Smoking Cessation Treatment for Young Adult Dual Users of Combustible and Electronic Cigarettes

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04946825
• Other study ID #: STUDY00001059
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 27, 2021
• Est. completion date: January 2024

Study information

• Verified date: July 2023
• Source: University of Vermont
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching aim of this proposed randomized controlled trial (RCT) is to test nicotine replacement therapy (NRT) with text message support for two smoking cessation approaches among young adult dual users of combustible cigarettes (CC) and electronic cigarettes (EC). The investigators will use a 2x2 factorial design to randomize 390 participants to receive A) NRT plus text messages to quit CCs only, B) NRT plus text messages to quit CCs and ECs simultaneously, C) text messages alone to quit CCs only, or D) text messages alone to quit CCs and ECs simultaneously. The investigators primary outcome will be 7-day point-prevalence abstinence at the end of treatment (i.e., 3 months after randomization). The investigators will recruit participants using national advertising strategies. All treatment will be provided remotely in order to increase treatment access and comply with current COVID-19 restrictions.

Description:

The overarching aim of this proposed randomized controlled trial (RCT) is to test nicotine replacement therapy (NRT) with text message support for two smoking cessation approaches among young adult dual users of ombustible cigarettes (CC) and electronic cigarettes (EC). The investigators will use a 2x2 factorial design (Table 1) to randomize 390 participants to receive A) NRT plus text messages to quit CCs only, B) NRT plus text messages to quit CCs and ECs simultaneously, C) text messages alone to quit CCs only, or D) text messages alone to quit CCs and ECs simultaneously. The investigators' primary outcome will be 7-day point-prevalence abstinence at the end of treatment (i.e., 3 months after randomization). All treatment will be provided remotely in order to increase treatment access and comply with COVID-19 restrictions. The proposed RCT addresses the following specific aims:

Aim 1: To test whether NRT is an effective smoking cessation treatment for young adult dual users of ECs and CCs.

Aim 2: To identify the influence of continued EC use versus stopping ECs on achieving CC abstinence among young adult dual users of ECs and CCs.

Aim 3: To identify whether continued EC use results in more acute adverse events than stopping ECs among young adult dual users who are quitting CCs.

The investigators will recruit and consent 390 participants with the aim of retaining 312 (80%) by the end of treatment. Participants in each condition will complete a survey at baseline, weekly surveys throughout the 3-month treatment period, brief daily surveys for one week before and one week after the assigned quit date, an end of treatment survey, and a survey at a follow-up 6 months after treatment began. In addition, participants will provide breath CO samples at baseline, all weekly surveys, the end of treatment, and the 6-month follow-up using the CoVita iCO personal smokerlyzer (https://www.covita.net/ico-overview/).

All assessments will be remote and accessible by smartphone, tablet, or computer. After confirming eligibility and consenting to participate, participants will be randomly assigned to one of the four study groups and study personnel will mail a welcome package including study information, a CoVita iCO personal smokerlyzer device, and NRT (for groups A and B only). Upon receipt of the welcome package, participants will complete a brief baseline survey on the internet and provide a baseline breath CO sample using the CoVita iCO device and Vincere Health mobile application which is compatible with Mac iOS and Android operating systems for smartphones and tablets. The investigators will not ask participants to return their personal CoVita iCO Smokerlyzer. All participants will be free to keep their personal CoVita iCO Smokerlyzer after the conclusion of their participation.

All participants will complete brief daily surveys for two weeks: one week pre- and one week post-quit date. Participants will receive a daily text and/or email containing a link for the daily survey and will be able to complete the survey via internet on a smartphone, tablet or computer. Participants will report CC smoking, EC use, NRT use (groups A and B only), text message utilization, nicotine dependence, quit attempts, and adverse events on daily surveys (Table 2). At the conclusion of the 12-week treatment period, participants will complete an end of treatment survey to report CC smoking or EC use and withdrawal symptoms. Those still smoking will also report motivation to quit, nicotine dependence, and self-efficacy to quit. In addition, participants will provide another breath CO sample using their CoVita iCO device. The primary outcome for this RCT is CO confirmed 7-day point-prevalence abstinence from CCs at the end of treatment (i.e., at the 3-month follow-up). Per the Society for Research on Nicotine and Tobacco (SRNT) report on biochemical verification, the investigators will use CO of < 6 parts per million (ppm) as the cutoff for confirming CC abstinence. The investigators will not contact participants for the 12 weeks following the treatment period. All participants will then complete a 6-month follow-up survey (i.e., 24 weeks after the baseline assessment) to report any CC smoking or EC use and withdrawal symptoms. Those who relapsed or continued to smoke CCs will also report motivation to quit, nicotine dependence, and self-efficacy to quit. In addition, all participants will provide a final breath CO sample using their CoVita iCO device.

Treatment. The consent form explains that a primary aim of this RCT is to test whether quitting versus continuing ECs is more effective when quitting CCs, and currently there is mixed evidence supporting both strategies. After randomization, all participants will receive information about the study including instructions to set a quit date and which product(s) to quit. Written instructions for the intervention will be provided and participants will also be asked to view a supplementary video presentation. The investigators will provide participants in groups A and C with instructions to quit CCs but continue using ECs with the rationale that ongoing use of ECs could help them abstain from CCs. Specifically, the investigators will instruct participants in groups A and C to use ECs in place of CCs to help cope with cravings or urges to smoke CCs. In contrast, participants randomized to conditions B and D will receive instructions to quit CCs and quit ECs with the rationale that quitting ECs could help them abstain from CCs. The investigators will instruct participants in groups B and D to abstain from vaping because ECs could trigger relapse to CCs. Participants in groups A and B will also receive instructions for how to use NRT.

Participants randomized to conditions A and B will be mailed 3 one-month supplies of dual 14 mg NRT patches and 4 mg mini-lozenge because this appears to be the most effective non-prescription medication combination for smoking cessation However, participants will have the option to stop receiving NRT from the study. Participants will be instructed to start using both forms of NRT 2 weeks prior to their quit date because pre-quit NRT appears to increase the effectiveness of NRT. Further, the recommended use for the NRT has recently been changed to incorporate use while smoking because "the FDA has determined that there are no significant concerns with using NRT products at the same time as another nicotine-containing product like a cigarette (https://www.nicodermcq.com/faq.html)." The investigators will instruct participants to use one patch per day and use mini-lozenges when they have cravings to smoke CCs (condition A) or cravings to smoke CCs or use ECs (condition B), without surpassing 24 mini-lozenges in one 24-hour period. Anyone for whom NRT is contraindicated will be excluded from the proposed RCT. In addition, though risk of serious adverse events from NRT is low, the investigators will assess adverse events related to study procedures on nightly surveys.

All participants will receive daily text message support throughout the 12-week treatment period. The investigators will modify a text message library from SmokefreeTXT, a free interactive text message cessation service provided by Smokefree.gov that has been used with young adult smokers, uses empirically validated Behavior Change Techniques, and has been employed to support engagement in prior smoking cessation research. Data from the investigators' ongoing research indicate young adult smokers generally find daily text messages to be helpful and acceptable. The investigators will modify text messages according to participants' assigned group. For example, text messages for participants in groups A and B will encourage regular use of NRT throughout the study period. Text messages for groups B and D will support CC and EC cessation while messages for groups A and C will support CC cessation and EC continuation. The text message service will be interactive for all participants. In addition to receiving daily texts, participants will have the opportunity to send text messages to the investigators' service which will prompt automatic responses. The investigators will work with ICF incorporated, the provider for National Cancer Institute's SmokefreeTXT platform, to deliver all daily text messages and to deliver links to daily surveys.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 390
• Est. completion date: January 2024
• Est. primary completion date: September 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 29 Years

Eligibility

Inclusion criteria:

• Young adult

• Smokes tobacco cigarettes

• Uses electronic cigarettes

• Interested in quitting tobacco

Exclusion criteria:

• Pregnant or planning to become pregnant

• Breastfeeding or planning to start breastfeeding

• One or more contraindications for nicotine replacement therapy

Additional criteria will be assessed to determine eligibility.

If you are interested in participating, please visit the study website to find out if you are eligible: https://www.uvmquitsmokingstudy.org/

Related Conditions & MeSH terms

• E-Cig Use
• Nicotine Addiction
• Quitting Smoking
• Tobacco Use Disorder

Intervention

Drug:
• Nicotine replacement therapy patch
The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
• Nicotine replacement therapy lozenge
The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.

Behavioral:
• Quit electronic cigarettes
Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
• Continue electronic cigarettes
Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.

Locations

Country	Name	City	State
United States	University of Vermont	Burlington	Vermont

Sponsors (1)

Lead Sponsor	Collaborator
University of Vermont

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biochemically confirmed 7-day point-prevalence cigarette abstinence	The investigators will report CO confirmed 7-day point-prevalence abstinence from combustible cigarettes at the end of treatment.	End of treatment (ie., the 3 month follow up)
Primary	Self-reported 7-day point-prevalence cigarette abstinence	The investigators will report self-reported 7-day point-prevalence abstinence from combustible cigarettes at the end of treatment.	End of treatment (ie., the 3 month follow up)
Primary	Adverse events during treatment	The investigators will report self-reported adverse events during the 3-month treatment period.	The 3 month treatment period.
Secondary	Biochemically confirmed prolonged 30-day abstinence	The investigators will report CO confirmed 30-day prolonged abstinence from combustible cigarettes at the 6 month follow up.	The 3-month follow up (ie., end of treatment) and 6-month follow up (3 months after the end of treatment).
Secondary	Self-reported prolonged 30-day abstinence	The investigators will report self-reported 30-day prolonged abstinence from combustible cigarettes at the 6 month follow up.	The 3-month follow up (ie., end of treatment) and 6-month follow up (3 months after the end of treatment).
Secondary	Attempts to quit combustible cigarettes lasting 24 hours or more	The investigators will report the proportion of participants who made a quit attempt lasting 24 hours or more during treatment.	The 3-month treatment period.
Secondary	Any attempts to quit combustible cigarettes	The investigators will report the proportion of participants who made a quit attempt lasting any length of time (including very short quit attempts) during treatment.	The 3-month treatment period.
Secondary	Cigarettes per day	The investigators will report change in cigarettes per day during the 3 month treatment period among participants who continue to smoke cigarettes.	The 3-month treatment period.
Secondary	Cigarette dependence	The investigators will report change in dependence using the PROMIS nicotine dependence measure during the 3 month treatment period among participants who continue to smoke cigarettes.	The 3-month treatment period.

External Links

•   Study website with more information about the study and a survey to find out if you are eligible to participate.